JP2018521133A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521133A5 JP2018521133A5 JP2018521498A JP2018521498A JP2018521133A5 JP 2018521133 A5 JP2018521133 A5 JP 2018521133A5 JP 2018521498 A JP2018521498 A JP 2018521498A JP 2018521498 A JP2018521498 A JP 2018521498A JP 2018521133 A5 JP2018521133 A5 JP 2018521133A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- item
- selective
- platinum drug
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 150
- 108091006735 SLC22A2 Proteins 0.000 claims description 91
- 102100032417 Solute carrier family 22 member 2 Human genes 0.000 claims description 91
- 229910052697 platinum Inorganic materials 0.000 claims description 75
- 239000003814 drug Substances 0.000 claims description 73
- 239000003112 inhibitor Substances 0.000 claims description 72
- 229940079593 drug Drugs 0.000 claims description 65
- 206010029350 Neurotoxicity Diseases 0.000 claims description 29
- 206010044221 Toxic encephalopathy Diseases 0.000 claims description 29
- 231100000228 neurotoxicity Toxicity 0.000 claims description 29
- 230000007135 neurotoxicity Effects 0.000 claims description 29
- OWYLAEYXIQKAOL-UHFFFAOYSA-N 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone Chemical class COC1=CC(OC)=CC(OC)=C1C(=O)CCCN1CCCC1 OWYLAEYXIQKAOL-UHFFFAOYSA-N 0.000 claims description 23
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 23
- 230000001988 toxicity Effects 0.000 claims description 23
- 231100000419 toxicity Toxicity 0.000 claims description 23
- 229960001756 oxaliplatin Drugs 0.000 claims description 21
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 16
- 229960004316 cisplatin Drugs 0.000 claims description 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 13
- 229960002542 dolutegravir Drugs 0.000 claims description 11
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 11
- 230000036470 plasma concentration Effects 0.000 claims description 11
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 9
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 238000001990 intravenous administration Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000001186 cumulative effect Effects 0.000 claims description 7
- 108091006744 SLC22A1 Proteins 0.000 claims description 6
- 102100032416 Solute carrier family 22 member 1 Human genes 0.000 claims description 6
- 102100036929 Solute carrier family 22 member 3 Human genes 0.000 claims description 6
- 101710102693 Solute carrier family 22 member 3 Proteins 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- 210000003594 spinal ganglia Anatomy 0.000 claims description 4
- 206010029155 Nephropathy toxic Diseases 0.000 claims description 3
- 206010033109 Ototoxicity Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 3
- 230000007694 nephrotoxicity Effects 0.000 claims description 3
- 231100000262 ototoxicity Toxicity 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 210000001044 sensory neuron Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 16
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 231100000189 neurotoxic Toxicity 0.000 claims 1
- 230000002887 neurotoxic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 90
- 206010028980 Neoplasm Diseases 0.000 description 31
- 201000011510 cancer Diseases 0.000 description 31
- 229960001415 buflomedil Drugs 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001953 sensory effect Effects 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004899 motility Effects 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 230000008447 perception Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960000397 bevacizumab Drugs 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 3
- 235000008191 folinic acid Nutrition 0.000 description 3
- 239000011672 folinic acid Substances 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 229960001691 leucovorin Drugs 0.000 description 3
- 150000002892 organic cations Chemical class 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 235000020004 porter Nutrition 0.000 description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000208125 Nicotiana Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000017215 gastric mucosa-associated lymphoid tissue lymphoma Diseases 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000008035 nerve activity Effects 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 201000000267 smooth muscle cancer Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 206010073360 Appendix cancer Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 201000004085 CLL/SLL Diseases 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102100032877 Multidrug and toxin extrusion protein 1 Human genes 0.000 description 1
- 101710132465 Multidrug and toxin extrusion protein 1 Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- -1 OCT-3 Proteins 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000006966 adult T-cell leukemia Diseases 0.000 description 1
- 201000008170 anus adenocarcinoma Diseases 0.000 description 1
- 208000021780 appendiceal neoplasm Diseases 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
- 231100000026 common toxicity Toxicity 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 210000000658 ulnar nerve Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193529P | 2015-07-16 | 2015-07-16 | |
| US62/193,529 | 2015-07-16 | ||
| PCT/US2016/042673 WO2017011816A1 (en) | 2015-07-16 | 2016-07-15 | Methods of preventing toxicity of platinum drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021033324A Division JP7117797B2 (ja) | 2015-07-16 | 2021-03-03 | プラチナ薬剤の毒性の予防方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521133A JP2018521133A (ja) | 2018-08-02 |
| JP2018521133A5 true JP2018521133A5 (https=) | 2019-08-29 |
| JP6851639B2 JP6851639B2 (ja) | 2021-03-31 |
Family
ID=57757682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018521498A Expired - Fee Related JP6851639B2 (ja) | 2015-07-16 | 2016-07-15 | プラチナ薬剤の毒性の予防方法 |
| JP2021033324A Active JP7117797B2 (ja) | 2015-07-16 | 2021-03-03 | プラチナ薬剤の毒性の予防方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021033324A Active JP7117797B2 (ja) | 2015-07-16 | 2021-03-03 | プラチナ薬剤の毒性の予防方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11197862B2 (https=) |
| EP (2) | EP3777851B1 (https=) |
| JP (2) | JP6851639B2 (https=) |
| CN (1) | CN108024986A (https=) |
| CA (1) | CA2990686A1 (https=) |
| WO (1) | WO2017011816A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2990686A1 (en) * | 2015-07-16 | 2017-01-19 | Amari Biopharma, Inc. | Methods of preventing toxicity of platinum drugs comprising administering an oct monitor |
| KR101859922B1 (ko) * | 2017-02-07 | 2018-05-21 | 주식회사 온코크로스 | 클로페네신을 포함하는 대장암 증식 및 전이 억제용 조성물 |
| CN109596818B (zh) * | 2018-12-13 | 2024-03-19 | 丁蓉 | 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法 |
| US20220125877A1 (en) * | 2019-07-10 | 2022-04-28 | Sun Yat-Sen University | Method for treating colorectal cancer |
| WO2021034627A1 (en) * | 2019-08-16 | 2021-02-25 | Purdue Research Foundation | Small molecule stimulators of the core particle of the proteasome |
| CN111067894A (zh) * | 2020-01-14 | 2020-04-28 | 广东药科大学 | 咪康唑在制备抗肺鳞癌药物和顺铂增敏剂中的应用 |
| CN111110675A (zh) * | 2020-02-25 | 2020-05-08 | 浙江大学 | 延胡索乙素在制备抗奥沙利铂外周神经毒性药物中的应用 |
| CN113527333B (zh) * | 2020-04-13 | 2022-08-05 | 南开大学 | 具有生物活性的度鲁特韦衍生物及其制备方法和应用 |
| WO2022244757A1 (ja) | 2021-05-18 | 2022-11-24 | 株式会社Ｌｔｔバイオファーマ | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009032172A2 (en) * | 2007-08-31 | 2009-03-12 | Massachusetts Institute Of Technology | Platinum compositions as treatment for oct-related cancers |
| ES2665042T3 (es) | 2008-02-18 | 2018-04-24 | Laboratorios Del Dr. Esteve, S.A. | Uso de compuestos que se unen a ligandos del receptor sigma para el tratamiento del dolor neuropático que se desarrolla como consecuencia de la quimioterapia |
| EP2090311A1 (en) * | 2008-02-18 | 2009-08-19 | Laboratorios Del. Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| HUE029661T2 (en) | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
| EP2854829A1 (en) * | 2012-05-30 | 2015-04-08 | Sensorion | Methods for treating vestibulotoxicity |
| CA2891855A1 (en) | 2012-12-21 | 2014-06-26 | Sykehuset Sorlandet Hf | Egfr targeted therapy of neurological disorders and pain |
| CA2990686A1 (en) * | 2015-07-16 | 2017-01-19 | Amari Biopharma, Inc. | Methods of preventing toxicity of platinum drugs comprising administering an oct monitor |
-
2016
- 2016-07-15 CA CA2990686A patent/CA2990686A1/en active Pending
- 2016-07-15 CN CN201680053118.8A patent/CN108024986A/zh active Pending
- 2016-07-15 EP EP20198351.7A patent/EP3777851B1/en active Active
- 2016-07-15 US US15/744,485 patent/US11197862B2/en active Active
- 2016-07-15 EP EP16825297.1A patent/EP3322414B1/en active Active
- 2016-07-15 JP JP2018521498A patent/JP6851639B2/ja not_active Expired - Fee Related
- 2016-07-15 WO PCT/US2016/042673 patent/WO2017011816A1/en not_active Ceased
-
2021
- 2021-03-03 JP JP2021033324A patent/JP7117797B2/ja active Active
- 2021-12-06 US US17/543,504 patent/US20220202823A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018521133A5 (https=) | ||
| Balayssac et al. | Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence | |
| Aghajanian et al. | A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies | |
| Rosenne et al. | In vivo suppression of NK cell cytotoxicity by stress and surgery: glucocorticoids have a minor role compared to catecholamines and prostaglandins | |
| Muñoz et al. | The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists | |
| BR112019017851A2 (pt) | método para tratar câncer em um indivíduo que precisa do mesmo, método para identificar um indivíduo que tem um câncer como um candidato para o tratamento com um antagonista de smarca2, método para identificar uma célula cancerosa como sensível ao tratamento com um antagonista de smarca2, antagonista de smarca2 para uso no tratamento de câncer em um indivíduo que precisa do mesmo, antagonista de smarca2 para uso como um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo e uso do antagonista de smarca2 na fabricação de um medicamento no tratamento de câncer em um indivíduo que precisa do mesmo | |
| Nemunaitis et al. | Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors | |
| He et al. | Cephalosporin antibiotics specifically and selectively target nasopharyngeal carcinoma through HMOX1-induced ferroptosis | |
| JP2016520528A5 (https=) | ||
| KR20180064438A (ko) | Ｎａｓｈ-연관 간암의 치료를 위한 ｅｐ4 수용체 길항제의 용도 | |
| JP2019530706A5 (https=) | ||
| US20220142979A1 (en) | Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease | |
| CN107683139A (zh) | 用于治疗b细胞恶性肿瘤的赛度替尼 | |
| WO2020132259A1 (en) | Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a) | |
| He et al. | Dihydroergotamine mesylate enhances the anti-tumor effect of sorafenib in liver cancer cells | |
| Naeem et al. | Fenoldopam for the prevention of contrast-induced nephropathy (CIN)—do we need more trials? A meta-analysis | |
| PT1885187E (pt) | Métodos para o tratamento de cancro resistente a fármacos | |
| Reikvam et al. | Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1)–gene transcription, cell cycle regulation, metabolism and intercellular communication | |
| Palaniappan et al. | Anticancer drug induced palmar plantar erythrodysesthesia | |
| US12514863B2 (en) | Pharmaceutical combination and use thereof | |
| Zhang et al. | Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma | |
| Goyal et al. | Ionotropic glutamate receptors and their implications in cancer and cancer therapeutics | |
| Cheney et al. | Antiretroviral Drugs Impact Autophagy: Opportunities for Drug Repurposing | |
| US20200230247A1 (en) | Combination therapies comprising targeted therapeutics | |
| ES2266590T3 (es) | Uso de una combinacion que comprende 4-pirilmetilftalazinas para el tratamiento de cancer. |